NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Spyre’s SPY001 Delivers Strong Early Results in Ulcerative Colitis Trial – Shares Jump

Spyre drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.

Spyre’s SPY001 Delivers Strong Early Results in Ulcerative Colitis Trial – Shares Jump
Credit: Spyre Therapeutics
Already have an account? Sign in.
04/13/2026 · 8:50 AM
SYRE
/ Don’t stop at just one post.

Related↓

Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns
07/28/2026 · 9:24 AM

Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns

Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.

/ Subscriber only
/ Read more

Feed↓

Prince Alwaleed Buys 5% of Lucid Motors Amid Stock Volatility
07/28/2026 · 1:28 PM

Prince Alwaleed Buys 5% of Lucid Motors Amid Stock Volatility

Saudi billionaire Prince Alwaleed acquires 19.5M shares of Lucid, taking a 5% stake after the stock’s sharp mid-July drop.

/ Subscriber only
Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Featured/ 07/28/2026 · 1:04 PM

Prelude Shares Jump as Incyte Drops Rival JAK2 Drug

Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.

/ Subscriber only
FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel
Featured/ 07/28/2026 · 12:39 PM

FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel

FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe